Welcome to our dedicated page for Burning Rock Biotech news (Ticker: BNR), a resource for investors and traders seeking the latest updates and insights on Burning Rock Biotech stock.
Burning Rock Biotech Limited (NASDAQ: BNR) is a cancer diagnostics company focused on applying next generation sequencing (NGS) technology to precision oncology. The BNR news stream features company announcements on therapy selection testing, early cancer detection programs, pharmaceutical collaborations and financial performance.
In its press releases, Burning Rock regularly reports quarterly and annual financial results, with details on revenues from its central laboratory business, in-hospital business and pharma research and development services. These updates often include commentary on gross margins, operating expenses, and the mix of revenue from Mainland China and overseas customers.
News about Burning Rock also covers scientific and clinical milestones. The company highlights study results on circulating tumor DNA (ctDNA), minimal residual disease (MRD) monitoring, and multi-cancer early detection, presented at major conferences and in journals. It reports on the progress of products such as OncoScreen™ Plus, the CanCatch® Custom MRD assay, and multi-omics early detection tests that have advanced into clinical validation.
Another key theme in BNR news is companion diagnostics and pharmaceutical partnerships. Burning Rock has announced CDx collaborations, regulatory approvals such as the OncoGuide™ OncoScreen™ Plus CDx System in Japan, and an NMPA-approved NGS-based CDx for EGFR exon 20 insertion mutation in lung cancer. Corporate governance items, including annual general meeting results and auditor appointments, also appear in the company’s news flow.
Investors and healthcare professionals can use this news page to follow Burning Rock’s disclosures on its precision oncology platform, business segment trends, regulatory developments and scientific achievements related to BNR stock.
Burning Rock (NASDAQ: BNR) announced on Jan 5, 2026 that its founder, chairman and CEO Yusheng Han purchased US$811,721.28 of the company’s ADSs from the open market.
The company said the purchases were executed in compliance with applicable rules, the company’s insider trading policy, and may be continued through open-market transactions, privately negotiated trades or block trades depending on market conditions. The announcement notes timing will follow Rule 10b-18 and Rule 10b5-1 requirements and company policy.
Burning Rock (NASDAQ: BNR) announced that all shareholder resolutions at its 2025 annual general meeting held on Dec. 22, 2025 were duly passed.
Passed resolutions include: ratification of Ernst & Young Hua Ming LLP as auditor for the fiscal year ending Dec. 31, 2025 with directors authorized to set auditor remuneration; re-election of Feng Deng and Licen Lisa Xu as directors; and authorization for directors to take actions necessary to implement these resolutions.
Burning Rock Biotech (NASDAQ: BNR) will hold its 2025 Annual General Meeting on December 23, 2025 at 10:30 a.m. local time at its Shanghai office: 6/F, Building 10C, Pujiang Smart Plaza, No. 2168 Chenhang Highway, Minhang District, Shanghai.
The AGM agenda includes ratifying the appointment of Ernst & Young Hua Ming LLP as auditor for the year ending December 31, 2025, re-election of Feng Deng and Licen Lisa Xu as directors, and authorizing directors to take actions to effect those resolutions. The board recommends shareholders and ADS holders vote in favor.
The record date for shareholders entitled to notice is December 1, 2025 (New York time). ADS holders must instruct Citibank, N.A. to vote underlying Class A shares. Burning Rock filed its Form 20-F with audited financials for year ended December 31, 2024.
Burning Rock (NASDAQ: BNR) reported results for Q3 2025 ended September 30, 2025. Total revenue was RMB131.6 million (US$18.5 million), up 2.3% year‑over‑year. Pharma R&D revenue rose 68.6% to RMB42.0 million (US$5.9 million). Gross profit was RMB98.8 million (US$13.9 million) with gross margin improving to 75.1% from 71.4% (≈370 bps). Operating expenses declined 11.9% to RMB115.0 million (US$16.2 million). Net loss narrowed to RMB16.8 million (US$2.4 million) from RMB35.7 million a year earlier. Cash and equivalents were RMB467.0 million (US$65.6 million) as of September 30, 2025.
Business highlights: MHLW approved OncoGuide OncoScreen Plus CDx for AstraZeneca capivasertib in Japan; PROMISE and clinical study results presented in September 2025 showing improved multimodal detection sensitivity.
Burning Rock Biotech (NASDAQ: BNR) and Riken Genesis have received approval from Japan's MHLW for their OncoGuide™ OncoScreen™ Plus CDx System as a companion diagnostic for AstraZeneca's capivasertib in breast cancer treatment.
The CDx System is designed to detect PIK3CA, AKT1, and PTEN alterations in a single test, supporting treatment decisions for adult patients with unresectable or recurrent HR-positive, HER2-negative breast cancer who have progressed after endocrine therapy. The diagnostic will be used for patient selection for capivasertib in combination with fulvestrant.
Riken Genesis will proceed with insurance coverage preparations to ensure patient access, while Burning Rock is advancing the product's registration in China.
Burning Rock Biotech (NASDAQ: BNR), a precision oncology NGS technology company, reported its Q2 2025 financial results with total revenues of RMB148.5 million (US$20.7 million), representing a 9.6% year-over-year increase.
The company's performance showed mixed results across segments: in-hospital business grew 4.4% to RMB62.5 million, central laboratory business declined 16.2% to RMB40.9 million, while pharma R&D services surged 68.1% to RMB45.2 million. Gross margin improved to 72.8% from 70.4% year-over-year.
Operating expenses decreased significantly by 42.1% to RMB119.6 million due to budget control measures and headcount reduction. The company narrowed its net loss to RMB9.7 million from RMB108.0 million in the previous year.
Burning Rock Biotech (NASDAQ: BNR) has reported its Q4 and full-year 2024 financial results, showing mixed performance across different business segments. Q4 revenues increased 4.1% to RMB126.0 million (US$17.3 million), with a notable 50.9% growth in in-hospital business to RMB43.5 million, while central laboratory revenue declined 23.4% to RMB39.3 million.
The company's gross margin improved to 71.0% in Q4 2024 from 64.5% in Q4 2023. Operating expenses decreased by 29.9% to RMB171.3 million, driven by organizational optimization and cost-control measures. Net loss for Q4 2024 narrowed to RMB81.3 million (US$11.1 million) from RMB162.2 million in the prior year.
For full-year 2024, total revenue decreased 4.0% to RMB515.8 million, with in-hospital business growing 19.0% while central laboratory revenue declined 24.6%. The company's net loss for 2024 improved to RMB346.6 million from RMB653.7 million in 2023.
Burning Rock Biotech (NASDAQ: BNR), a company specializing in NGS technology for precision oncology, announced that all resolutions proposed at its 2024 annual general meeting were approved by shareholders. The key resolutions included: the ratification of Ernst & Young Hua Ming LLP as the company's auditor for fiscal year 2024, the re-election of directors Yusheng Han and Gang Lu, and the authorization for directors to implement these resolutions at their discretion.
Burning Rock Biotech (NASDAQ: BNR) reported Q3 2024 financial results with total revenues of RMB128.6 million (US$18.3 million), a 0.8% increase year-over-year. The company saw a 17% growth in in-hospital business revenue to RMB63.8 million, while central laboratory revenue decreased 25.2% to RMB40.0 million. Pharma R&D services revenue increased 27.1% to RMB24.9 million.
The company's gross profit increased 6.9% to RMB91.8 million, with gross margin improving to 71.4% from 67.4%. Operating expenses decreased 50.7% to RMB130.4 million due to reduced share-based compensation and improved efficiency. Net loss narrowed to RMB35.7 million from RMB175.0 million in the previous year. Cash and equivalents stood at RMB498.2 million as of September 30, 2024.
FAQ
What is the current stock price of Burning Rock Biotech (BNR)?
What is the market cap of Burning Rock Biotech (BNR)?
